• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 20-F/A filed by IM Cannabis Corp.

    9/19/24 11:54:29 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $IMCC alert in real time by email
    IM Cannabis Corp. - 1792030 - 2024
    trueFY0001792030 0001792030 2023-01-01 2023-12-31 0001792030dei:BusinessContactMember 2023-01-01 2023-12-31 0001792030 2023-12-31 xbrli:shares

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549
     
    FORM 20-F/A
     
    (Amendment No. 1)
     
    ☐
    REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    OR
     
    ☒
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2023
     
    OR
     
    ☐
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from ____________________ to ____________________
     
    OR
     
    ☐
    SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    Commission file number: 001-40065
     
    IM Cannabis Corp.
    (Exact name of Registrant as specified in its charter)
     
    British Columbia, Canada
    (Jurisdiction of incorporation or organization)
     
    3606 – 833 Seymour Street, Vancouver, British Columbia V6B 0G4
    (Address of principal executive offices)
     
    Oren Shuster, 972 544331111, [email protected]
    3606 – 833 Seymour Street, Vancouver, British Columbia V6B 0G4
    (Name, Telephone, E-Mail and/or Facsimile number and Address of Company Contact Person)
     
    Securities registered or to be registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol
    Name of each exchange on which registered
    Common Shares, no par value
    IMCC
    Nasdaq Capital Market
     
    Securities registered or to be registered pursuant to Section 12(g) of the Act: N/A
     
    Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
     
    Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 13,394,136 Common Shares
     

    Indicate by check mark if the Company is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
     
    Yes ☐          No ☒
     
    If this report is an annual or transition report, indicate by check mark if the Company is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
     
    Yes ☐          No ☒
     
    Indicate by check mark whether the Company (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
     
    Yes ☒          No ☐
     
    Indicate by check mark whether the Company has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Company was required to submit and post such files).
     
    Yes ☒          No ☐
     
    Indicate by check mark whether the Company is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filer ☐
    Accelerated filer ☐
    Non-accelerated filer ☒
    Emerging growth company ☒
     
    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
     
    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
     
    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
     
    Indicate by check mark which basis of accounting the Company has used to prepare the financial statements included in this filing:
     
    U.S. GAAP ☐
    International Financial Reporting Standards as issued By the International
    Accounting Standards Board ☒
    Other ☐
     
    If “Other” has been checked in response to previous question, indicate by check mark which financial statement item the Company has elected to follow. Item 17 ☐ Item 18 ☐
     
    If this is an annual report, indicate by check mark whether the Company is a shell company (as defined in Rule 12b-2 of the Exchange Act).
     
    Yes ☐          No ☒
     

    EXPLANATORY NOTE
     
    This Amendment No. 1 on Form 20-F/A (this “Amendment”) amends the Annual Report on Form 20-F of IM Cannabis Corp. (the “Company,” “IMC,” “Group,” “we,” “us,” and “our”) for the year ended December 31, 2023, which was originally filed with the Securities and Exchange Commission on March 28, 2024 (the “Original Filing” and together with this Amendment, the “Annual Report”).
     
    The Company is filing this Amendment in order to file Exhibit 97 to the Annual Report – IM Cannabis Corp.’s Incentive Compensation Recovery Policy (the “Incentive Compensation Recovery Policy”).
     
    Pursuant to Rule 12b-15 under the Securities and Exchange Act of 1934, as amended, this Amendment also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Item 15 of Form 20-F, paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not including new certifications under Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) (Section 906 of the Sarbanes-Oxley Act of 2002), as no financial statements are being filed with this Amendment.
     
    Except as described above or as otherwise expressly provided by the terms of this Amendment, no other changes have been made to the Original Filing. Except as otherwise indicated herein, this Amendment continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events that occurred subsequent to the date of the Original Filing.
     

    ITEM 19. EXHIBITS
     
    The following are filed as exhibits hereto:
     
    12.1*
    Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934, filed herewith.
    12.2*
    Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934, filed herewith.
    97*
    IM Cannabis Corp. Incentive Compensation Recovery Policy
    101.INS**
     
    Inline XBRL Instance Document.
    101.SCH**
     
    Inline XBRL Taxonomy Extension Schema Document.
    101.CAL**
     
    Inline XBRL Taxonomy Extension Calculation Linkbase Document.
    101.DEF**
     
    Inline XBRL Taxonomy Extension Definition Linkbase Document.
    101.LAB**
     
    Inline XBRL Taxonomy Extension Label Linkbase Document.
    101.PRE**
     
    Inline XBRL Taxonomy Extension Presentation Linkbase Document.
    104
     
    Cover Page Interactive Data File – (formatted as Inline XBRL and contained in Exhibit 101)
     
    * filed herewith.
     
    ** furnished herewith.
     

    SIGNATURES
     
    The Registrant hereby certifies that it meets all of the requirements for filing this Amendment No. 1 on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.
     
    Date: September 19, 2024
    IM Cannabis Corp.
     
    By: /s/ Uri Birenberg
    Name: Uri Birenberg
    Title: Chief Financial Officer
     

     
    Get the next $IMCC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMCC

    DatePrice TargetRatingAnalyst
    10/5/2021$8.00Buy
    ROTH Capital
    7/14/2021Buy
    Desjardins
    7/14/2021$10.50Buy
    Desjardins
    More analyst ratings

    $IMCC
    SEC Filings

    View All

    SEC Form F-3 filed by IM Cannabis Corp.

    F-3 - IM Cannabis Corp. (0001792030) (Filer)

    2/5/26 4:45:37 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    1/26/26 5:12:29 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    1/5/26 9:09:42 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IM Cannabis Raises US$2,171,660.40 in Note Purchase Agreements

    TORONTO and GLIL YAM, Israel, Jan. 26, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced that it has raised a total of US$2,171,660.40 in debt financings from an arm's length third party (the "Lender") in order to manage the Company's current liquidity requirements. First Note Pursuant to a note purchase agreement between the Company and Lender dated January 7, 2026 (the "First Note Purchase Agreement"), the Company issued the Lender a note in the principal amount of US$1,538,749, after application of an original issuance discount of 10% (the "First Note"). The First Note b

    1/26/26 4:53:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces the Appointment of Mr. Alon Dayan to its Board of Directors

    TORONTO and GLIL YAM, Israel, Jan. 5, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), medical cannabis company with operations in Israel and Germany, announced today that Mr. Alon Dayan has been appointed to the Company's board of directors effective December 31, 2025. Mr. Dayan, who is currently the Chief Executive Officer of KeepZone AI Inc., a position he has held since 2025, brings over 15 years of executive experience in the homeland security technology sector, with a proven track record of founding and scaling innovative companies focused on systems integration, secure communications, and international business development. As the founder and Chief Execu

    1/5/26 8:55:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Explores U.S. Market Entry Following President Trump's Executive Order on Increasing Medical Marijuana and Cannabidiol Research

    Engages Exclusive Financial Advisors for U.S. Opportunities and Potential Divestitures of German and Israeli Operations TORONTO and GLIL YAM, Israel, Dec. 30, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), medical cannabis company with operations in Israel and Germany, today announced that it is actively evaluating certain strategic opportunities to expand its operations into the United States cannabis market. This initiative follows President Donald Trump's executive order signed on December 18, 2025, which directs the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, recognizing it

    12/30/25 7:42:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH Capital initiated coverage on IM Cannabis with a new price target

    ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00

    10/5/21 7:57:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IMC Mortgage Co

    Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy

    7/14/21 8:40:32 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IM Cannabis with a new price target

    Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50

    7/14/21 7:01:53 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Leadership Updates

    Live Leadership Updates

    View All

    IM Cannabis Announces the Appointment of Mr. Alon Dayan to its Board of Directors

    TORONTO and GLIL YAM, Israel, Jan. 5, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), medical cannabis company with operations in Israel and Germany, announced today that Mr. Alon Dayan has been appointed to the Company's board of directors effective December 31, 2025. Mr. Dayan, who is currently the Chief Executive Officer of KeepZone AI Inc., a position he has held since 2025, brings over 15 years of executive experience in the homeland security technology sector, with a proven track record of founding and scaling innovative companies focused on systems integration, secure communications, and international business development. As the founder and Chief Execu

    1/5/26 8:55:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Appoints Asi Levi as Chief Financial Officer

    TORONTO and GLIL YAM, Israel, Dec. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced, further to its press release dated October 29, 2025, the appointment of Asi Levi, CPA, as the Company's Chief Financial Officer ("CFO"), effective immediately, to replace Uri Birenberg. Mr. Levi has over 15 years of experience in finance and controlling roles, including serving as Chief Financial Officer of Water Ways Technologies Inc. and DekelOil CI, part of Dekel Agri-Vision Plc and as Controller of SciSparc Ltd. and A2Z Cust2Mate Solutions Corp. He has overseen fundraising efforts

    12/12/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

    TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

    9/11/24 8:30:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Financials

    Live finance-specific insights

    View All

    IM Cannabis Reports Third Quarter 2025 Financial Results

    TORONTO and GLIL YAM, Israel, Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated. Q3 2025 Financial Highlights:  Consistent Revenue for Q3 2025 and 2024 of $13.9 million.13% Gross profit decrease vs. Q3 2024 of $2.7 million vs. $3.1 million.13% Gross Margin decrease vs. Q3 2024 of 20% vs. 23%. $3.1 million One time goodwill and intangible asset impairment in Q3 2025 Operating

    11/13/25 9:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Second Quarter 2025 Financial Results

    IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights   14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M  306% Gross profit increase vs.

    8/12/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IM Cannabis Corp.

    SC 13G - IM Cannabis Corp. (0001792030) (Subject)

    2/21/23 10:56:41 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by IM Cannabis Corp. (Amendment)

    SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)

    2/8/23 1:29:15 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

    SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)

    2/2/23 10:38:01 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care